Upcoming Emyria CEO Webinars
Released
Released
Announcement PDF
ASX Announcement
7 December 2022
Upcoming Emyria CEO Webinars
Emyria Limited (ASX: EMD) (Emyria or the Company), a clinical stage biotech informed by
patient experience an tackling unmet needs in neuroscience & mental health, is pleased to invite
shareholders to two webinars.
Wednesday 07 December
12:00 pm AEDT
“THE INSIDER:
MEET THE CEOS”
&
Thursday 08 December
8.00am AEST
“PLANET MICROCAP
SHOWCASE: VIRTUAL 2022”
Emyria’s Managing Director Dr, Michael Winlo will discuss the latest updates on Emyria’s
clinical stage drug development programs and research, including the recently approved Phase
3 clinical trial of EMD-RX5 and the launch of their US-based preclinical activities for both the CBD
and MDMA inspired programs. The presentation deck “ Company Update is available now eon
the Emyria website. https://emyria.com/for-investors/
EVENT DETAILS - “THE INSIDER: MEET THE CEOS”
WEBINAR PRESENTER Emyria’s Managing Director, Dr. Michael Winlo
DATE Wednesday 07 December
TIME 12:00pm Sydney time (AEDT)
WHERE Webinar - details to be provided upon registration
TO REGISTER, please click on the link
https://reachmarkets.com.au/the-insider-mtc/
EVENT DETAILS - “PLANET MICROCAP SHOWCASE: VIRTUAL 2022”
WEBINAR PRESENTER Emyria’s Managing Director, Dr. Michael Winlo
DATE Thursday 08 December
TIME 8.00 am Sydney time (AEDT)
WHERE Webinar - details to be provided upon registration
TO REGISTER, please click on the link
https://www.webcaster4.com/Webcast/Page/2937/47234
Emyria ASX Announcement | 7 Dec 2022
2
ABOUT EMYRIA | emyria.com
Emyria Limited is a clinical drug development and care delivery company focused on
accelerating drug development and improving patient outcomes via:
●
Drug Development: Emyria has developed an Ultra-Pure cannabinoid platform that
can support the registration of multiple proprietary dose forms. Emyria’s first dose
form, EMD-RX5 is in Phase 3 trials
●
New Drug Discovery: Inspired by MDMA, Emyria is developing one of the world’s
largest libraries of MDMA-like compounds with partner, the University of
Western Australia.
●
Proprietary Real-World Data (RWD): Emyria gathers ethically-sourced data with
patients cared for at Emyria’s own specialist clinical service (Emerald Clinics).
Emyria RWD can help support drug development and care model improvement.
EMYRIA’S INTERACTIVE INVESTOR HUB investorhub.emyria.com
Interact with Emyria’s announcements and updates by asking questions and
comments, which our team can respond to where possible.
This announcement has been approved and authorised for release by the CEO.
FOR FURTHER INFORMATION
Dr. Michael Winlo
Managing Director
+61 (0) 8 6559 2800
mwinlo@emyria.com
Lexi O’Halloran
Investor Relations
+61 (0) 404 577 076
investors@emyria.com
Andrew Williams
Media Relations
+61 (0) 416 583 672
awilliams@emyria.com
CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS
Any statements in this press release about future expectations, plans and prospects for the Company,
the Company’s strategy, future operations, and other statements containing the words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements.
Actual results may differ materially from those indicated by such forward-looking statements as a
result of various important factors, including: the Company’s ability to successfully develop its
product candidates and timely complete its planned clinical programs and the Company’s ability to
obtain marketing approvals for its product candidates. In addition, the forward-looking statements
included in this press release represents the Company’s views as of the date hereof. The Company
anticipates that subsequent events and developments will cause the Company’s views to change.
However, while the Company may elect to update these forward-looking statements at some point
in the future, the Company specifically disclaims any obligation to do so. These forward-looking
statements should not be relied upon as representing the Company’s views as of any date
subsequent to the date hereof.
Emyria ASX Announcement | 7 Dec 2022
2
Share your feedback
Discover